Ab­b­Vie says it has pos­i­tive mid-stage da­ta for Rin­voq in lu­pus, will move to PhI­II

Ab­b­Vie is teas­ing new Phase II da­ta in the most com­mon form of lu­pus — and the phar­ma com­pa­ny says it is good enough to move in­to a piv­otal tri­al.

The drug com­pa­ny shared ini­tial re­sults Thurs­day, say­ing that its JAK block­buster Rin­voq met the pri­ma­ry goals of a Phase II tri­al in sys­temic lu­pus ery­the­mato­sus. The tri­al looked at whether Rin­voq led to a re­duc­tion of at least four points on a scor­ing sys­tem called SLE Dis­ease Ac­tiv­i­ty In­dex 2000 with­out the con­di­tion wors­en­ing over­all or the pa­tient de­vel­op­ing sub­stan­tial dis­ease ac­tiv­i­ty in new or­gans. It al­so re­quired that pa­tients not need more than a 10 mg dai­ly dose of steroid pred­nisone or an equiv­a­lent.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER